Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Actinium Pharmaceuticals, Inc. ATNM
$8.35
+$0.07 (0.85%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
212403306.00000000
-
week52high
15.12
-
week52low
4.67
-
Revenue
1030000
-
P/E TTM
-5669
-
Beta
0.39031100
-
EPS
-1.40000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 мая 2023 г. в 10:59
Описание компании
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| H.C. Wainwright | Buy | Buy | 04 июн 2020 г. |
| B. Riley FBR | Buy | Buy | 12 июл 2018 г. |
| B. Riley FBR | Buy | Buy | 06 дек 2017 г. |
| Roth Capital | Buy | Buy | 25 авг 2016 г. |
| H.C. Wainwright | Buy | Buy | 29 февр 2016 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SETH SANDESH | A | 305381 | 300000 | 17 авг 2022 г. |
| Nicholson, C. David | A | 72156 | 72156 | 01 июл 2022 г. |
| O'Loughlin Steve | A | 256348 | 256438 | 01 июл 2022 г. |
| Steinhart Richard I | A | 72156 | 72156 | 01 июл 2022 г. |
| Shetty Ajit | A | 72156 | 72156 | 01 июл 2022 г. |
| Chell Jeffrey W. | A | 72156 | 72156 | 01 июл 2022 г. |
| SETH SANDESH | A | 827366 | 827366 | 01 июл 2022 г. |
| Steinhart Richard I | A | 18351 | 18351 | 01 сент 2021 г. |
| Chell Jeffrey W. | A | 18351 | 18351 | 01 сент 2021 г. |
| Shetty Ajit | A | 18351 | 18351 | 01 сент 2021 г. |
Новостная лента
Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth
Investors Business Daily
24 февр 2023 г. в 14:16
Actinium has lofty ambitions to change the landscape of leukemia treatment. But ATNM stock cratered this week on final-phase test results.
Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023
PRNewsWire
14 февр 2023 г. в 07:30
- Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results - Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK , Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19, 2023 at the World Center Marriott in Orlando, Florida. Actinium will host an investor conference call and webcast to present full topline results from its pivotal Phase 3 SIERRA trial of Iomab-B at 6:00 PM EST on Saturday, February 18, 2023.
Actinium Pharmaceuticals: Prep For February
Seeking Alpha
10 янв 2023 г. в 04:23
Actinium Pharmaceuticals is delivering the goods on a deep pipeline of therapeutics. It has deepened its bench with experienced operators.
Actinium's stock jumps 22% on new data for its acute myeloid leukemia therapy
Market Watch
31 окт 2022 г. в 12:12
Shares of Actinium Pharmaceuticals Inc. ATNM, +24.20% were up 22.8% in trading on Monday after the company met the primary endpoint in a Phase 3 clinical trial for its investigational treatment for relapsed or refractory acute myeloid leukemia. Actinium said it plans to share additional clinical data by the end of the year.
Actinium (ATNM) Stock Pops on Positive Trial Results
InvestorPlace
31 окт 2022 г. в 11:41
Actinium Pharmaceuticals (NYSEMKT: ATNM ) stock is gaining on Monday after posting positive results from a Phase 3 clinical trial. The point of this clinical trial was to determine the effectiveness of Iomab-B in treating patients suffering from Elderly Relapsed or Refractory AML.